• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Baze’s Personalized Nutrition Supplement Service Closes $6M Series A

Share:

August 14, 2019

The startup plans to buff up its marketing as well as offer new tests and supplements.

Baze, a subscription platform that ships personalized vitamin supplement packages based on home blood test results, has raised $6 million in Series A funding. Supplement and wellness product manufacturer Nature’s Way headed the investment.

WHAT THEY DO

Looking to cut back on unnecessary supplement consumption and the costs it ensues, Baze’s direct-to-consumer service first tests the user to see which nutrients would provide the most benefit. The company sells a $99 starter kit that includes an at-home blood test. Once mailed back to Baze, consumers can view an analysis of their results through a mobile app, and decide whether to subscribe for a recurring shipment of their personalized supplement regiment.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Although Baze launched its service in 2018, a note on its website stresses that the product is only available if consumers agree to participate in an ongoing research study gauging user experiences with the at-home sample collection device.

WHAT IT’S FOR

The startup wrote in the announcement that it plans to build out its marketing to promote the benefits of individualized nutritional supplements among consumers. It is also looking to add to its collection of tests and supplements with new offerings.

“We are at a pivotal growth point for Baze — it’s exciting to see how our offerings are evolving with the needs of our consumers and the world,” Philipp Schulte, cofounder and CEO of Baze, said in a statement. “The partnership with Nature’s Way is an amazing stamp of approval from the quality leader in the US supplement market. … While we retain full independence, their support will be tremendous for making our mission of driving real health impact through truly personalized supplementation a reality.”

MARKET SNAPSHOT

Baze finds itself in fairly well-funded company, with both Care/of and Wellnicity announcing investment rounds for their own supplement platforms. Near the end of that year, Pillsy subsidiary Stride Nutrition also announced a new service that would combine its medication adherence technology with mail-order nutrition products.

ON THE RECORD

“The technology and research developments used in this product are a game-changer for the vitamin supplement industry,” Mike Devereux, president and CEO of Nature’s Way, said in a statement. “The innovation behind Baze and the company’s determination to personalize a program that illustrates a baseline of nutrient compliance and creates the supporting vitamin protocols that assist in evolving to an even more optimal state of nutrient compliance is something we believe will help the consumer on their health journey. At Nature’s Way, we believe the most expensive supplement you will buy is the one that does not help you and our passion for assisting the wellness process is complemented by the Baze evidence-based approach.”

Date: August 14, 2019

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody SupplieQuanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplie
  • Global Parkinson’s Disease Drug Market Insights, Industry Expansion Strategies 2020-2026Global Parkinson’s Disease Drug Market Insights, Industry Expansion Strategies 2020-2026
  • COVID-19 Pandemic Further Exposes Systemic Racism…COVID-19 Pandemic Further Exposes Systemic Racism…
  • Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
  • Nurx Gets Another $52 Million to Deliver Mail-Order Birth Control, PrEP, STI Test KitsNurx Gets Another $52 Million to Deliver Mail-Order Birth Control, PrEP, STI Test Kits
  • Hepcidin Market Insights, Trends, Size, Share and Forecast 2020 – 2027Hepcidin Market Insights, Trends, Size, Share and Forecast 2020 – 2027
  • Pediatric Biofeedback Video Game Maker Mightier Lands Additional $250,000Pediatric Biofeedback Video Game Maker Mightier Lands Additional $250,000
  • Novant Health Acquires 3 Tenet Hospitals in South Carolina for $2.4BNovant Health Acquires 3 Tenet Hospitals in South Carolina for $2.4B

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications